scout
|Videos|September 23, 2020

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME